Otonomy Company
Otonomy work on cochlear synaptopathy as an underlying pathology in age-related and noise-induced hearing loss and is believed to contribute to the common difficulty of hearing speech in the presence of background noise
Technology:
Anti-infective Drugs
Industry:
Gene therapy, PharmTech
Headquarters:
San Diego, California, United States
Founded Date:
2008
Employees Number:
51-100
Funding Status:
Post-IPO Equity
Investors Number:
12
Total Funding:
458M
Estimated Revenue:
Less than $1M
Last Funding Date:
Apr 7, 2021
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership